Results 11 to 20 of about 9,230,509 (381)

Alzheimer's disease. [PDF]

Network: Computation in Neural Systems, 2011
Over the last three decades, advances in biochemical pathology and human genetics have illuminated one of the most enigmatic subjects in biomedicine--neurodegeneration.
D. Selkoe
semanticscholar   +5 more sources

Neuroinflammation in Alzheimer's disease [PDF]

The Lancet Neurology, 2015
Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release ...
M. Heneka, M. Carson, J. E. Khoury, G. Landreth, F. Brosseron, D. Feinstein, A. Jacobs, T. Wyss-Coray, T. Wyss-Coray, J. Vitorica, R. Ransohoff, K. Herrup, S. Frautschy, B. Finsen, Guy C. Brown, A. Verkhratsky, A. Verkhratsky, A. Verkhratsky, K. Yamanaka, J. Koistinaho, E. Latz, E. Latz, A. Halle, G. Petzold, T. Town, D. Morgan, M. Shinohara, V. Perry, C. Holmes, C. Holmes, N. Bazan, D. Brooks, S. Hunot, B. Joseph, N. Deigendesch, O. Garaschuk, E. Boddeke, C. Dinarello, J. Breitner, G. Cole, D. Golenbock, M. Kummer   +41 more
semanticscholar   +11 more sources

Alzheimer disease [PDF]

Nature Reviews Disease Primers, 2021
Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic neurodegenerative disease that causes an amnestic cognitive impairment in its prototypical presentation and non-amnestic cognitive impairment in its less common variants.
David S. Knopman, Helene Amieva, Ronald C. Petersen, Gäel Chételat, David M. Holtzman, Bradley T. Hyman, Ralph A. Nixon, David T. Jones   +7 more
openaire   +3 more sources

Alzheimer's disease

The Lancet, 2021
In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The most recent data indicate that, by 2050, the prevalence of dementia will double in Europe and triple worldwide, and that estimate is 3 times higher when based on a biological (rather than clinical) definition of Alzheimer's disease.
Scheltens, P, De Strooper, B, Kivipelto, M, Holstege, H, Chételat, G, Teunissen, CE, Cummings, J, van der Flier, WM   +7 more
openaire   +5 more sources

Epigenetics of Alzheimer’s Disease [PDF]

Biomolecules, 2021
There are currently no validated biomarkers which can be used to accurately diagnose Alzheimer’s disease (AD) or to distinguish it from other dementia-causing neuropathologies. Moreover, to date, only symptomatic treatments exist for this progressive neurodegenerative disorder.
Matea Nikolac Perkovic, Alja Videtic Paska, Marcela Konjevod, Katarina Kouter, Dubravka Svob Strac, Gordana Nedic Erjavec, Nela Pivac   +6 more
openaire   +4 more sources

Alzheimer’s disease [PDF]

Current Biology, 2018
The German psychiatrist and neuropathologist Alois Alzheimer was fascinated by the symptoms of Auguste D., a 50-year-old woman admitted to the Frankfurt Psychiatric Hospital in 1901 who suffered from memory disturbances, paranoia and progressive confusion. After her death and autopsy, Alzheimer described histological alterations in her brain that later
Grøntvedt, G., Navarro Schröder, T., Sando, S., White, L., Bråthen, G., Doeller, C.   +5 more
openaire   +5 more sources

A potential biomarker of cognitive impairment: The olfactory dysfunction and its genes expression

Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1884-1897, December 2022., 2022
Abstract Objective Accumulation evidence has reported that olfactory impairment may be an essential clinical marker and predictor of mild cognitive impairment or Alzheimer's disease. Method Participants were enrolled in the population‐based, prospective study in Fuxin county, Liaoning province, China between 2019 and 2021.
Jiayi Song, Jiahui Xu, Wei Yuan, Ruixue Li, Hui Guo, Hanshu Gao, Cuiying Gu, Wenjing Feng, Yanan Ma, Haiqiang Guo, Zhaoqing Sun, Liqiang Zheng   +11 more
wiley   +1 more source

Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE® system

Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1898-1909, December 2022., 2022
Abstract Objectives Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are well‐established in research settings, but their use in routine clinical practice remains a largely unexploited potential. Here, we examined the relationship between CSF biomarkers, measured by a fully automated immunoassay platform, and brain β‐amyloid (Aβ ...
Hisashi Nojima, Satoshi Ito, Akira Kushida, Aki Abe, Wataru Motsuchi, David Verbel, Manu Vandijck, Geert Jannes, Ina Vandenbroucke, Katsumi Aoyagi   +9 more
wiley   +1 more source

Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer disease

Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1926-1940, December 2022., 2022
Abstract Objective Endothelial dysfunction is an early and prevalent pathology in Alzheimer disease (AD). We here investigate the value of vascular endothelial‐cadherin (VEC) as a cerebrospinal fluid (CSF) marker of endothelial injury in preclinical AD.
Rawan Tarawneh, Rachel S. Kasper, Jessie Sanford, Chia‐Ling Phuah, Jason Hassenstab, Carlos Cruchaga   +5 more
wiley   +1 more source

COVID‐19 and the risk of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis

Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1953-1961, December 2022., 2022
Abstract Background The coronavirus disease 2019 (COVID‐19) pandemic has had an unprecedented impact on the healthcare system, economy, and society. Studies have reported that COVID‐19 may cause various neurologic symptoms, including cognitive impairment.
Hanyu Zhang, Zengyuan Zhou
wiley   +1 more source